Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0HCICC
ADC Name	WO2015095301A2 ADC-37
Synonyms	WO2015095301A2_ADC-37 Click to Show/Hide
Organization	GEIERSTANGER.Bernhard
Drug Status	Investigative
Indication	In total 1 Indication(s) Breast cancer [ICD11:2C60-2C65] Investigative
Drug-to-Antibody Ratio	4.6
	3D MOL	2D MOL
Antibody Name	Anti-HER2 antibody 20507		Antibody Info
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)		Antigen Info
Payload Name	Undisclosed
Linker Name	WO2015095301A2 ADC-37 linker

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 4 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	167	pM	CVCL_1569	Lung small cell carcinoma
Half Maximal Inhibitory Concentration (IC50)	968	pM	CVCL_0217	Acute megakaryoblastic leukemia
Half Maximal Inhibitory Concentration (IC50)	2.37	nM	CVCL_0379	Chronic myeloid leukemia
Half Maximal Inhibitory Concentration (IC50)	0.07	uM	CVCL_0065	T acute lymphoblastic leukemia

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 4 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	167.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Lung small cell carcinoma	NCI-H526 cells		CVCL_1569
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	968.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Acute megakaryoblastic leukemia	CMK-11-5 cells		CVCL_0217
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.37 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Chronic myeloid leukemia	KU812 cells		CVCL_0379
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

References

Ref 1	Cytotoxic peptides and conjugates thereof.